These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 30625040)
61. Quantitative analysis of background parenchymal enhancement in whole breast on MRI: Influence of menstrual cycle and comparison with a qualitative analysis. Jung Y; Jeong SK; Kang DK; Moon Y; Kim TH Eur J Radiol; 2018 Jun; 103():84-89. PubMed ID: 29803391 [TBL] [Abstract][Full Text] [Related]
62. Impact of Background Parenchymal Enhancement on Diagnostic Performance in Screening Breast MRI. Sippo DA; Rutledge GM; Mercaldo SF; Burk KS; Edmonds CE; Dang PA; Lehman CD Acad Radiol; 2020 May; 27(5):663-671. PubMed ID: 31327575 [TBL] [Abstract][Full Text] [Related]
64. Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging. King V; Kaplan J; Pike MC; Liberman L; David Dershaw D; Lee CH; Brooks JD; Morris EA Breast J; 2012; 18(6):527-34. PubMed ID: 23002953 [TBL] [Abstract][Full Text] [Related]
65. Association of Breast Cancer Odds with Background Parenchymal Enhancement Quantified Using a Fully Automated Method at MRI: The IMAGINE Study. Watt GP; Thakran S; Sung JS; Jochelson MS; Lobbes MBI; Weinstein SP; Bradbury AR; Buys SS; Morris EA; Apte A; Patel P; Woods M; Liang X; Pike MC; Kontos D; Bernstein JL Radiology; 2023 Sep; 308(3):e230367. PubMed ID: 37750771 [TBL] [Abstract][Full Text] [Related]
67. The correlation of background parenchymal enhancement in the contralateral breast with patient and tumor characteristics of MRI-screen detected breast cancers. Vreemann S; Gubern-Mérida A; Borelli C; Bult P; Karssemeijer N; Mann RM PLoS One; 2018; 13(1):e0191399. PubMed ID: 29351560 [TBL] [Abstract][Full Text] [Related]
68. Prediction of background parenchymal enhancement on breast MRI using mammography, ultrasonography, and diffusion-weighted imaging. Kawamura A; Satake H; Ishigaki S; Ikeda M; Kimura R; Shimamoto K; Naganawa S Nagoya J Med Sci; 2015 Aug; 77(3):425-37. PubMed ID: 26412889 [TBL] [Abstract][Full Text] [Related]
69. Effect of Background Parenchymal Enhancement on Pre-Operative Breast Magnetic Resonance Imaging: How It Affects Interpretation and the Role of Second-Look Ultrasound in Patient Management. Kim SY; Lee HS; Kim EK; Kim MJ; Moon HJ; Yoon JH Ultrasound Med Biol; 2016 Dec; 42(12):2766-2774. PubMed ID: 27658753 [TBL] [Abstract][Full Text] [Related]
70. Machine learning-based prediction of future breast cancer using algorithmically measured background parenchymal enhancement on high-risk screening MRI. Saha A; Grimm LJ; Ghate SV; Kim CE; Soo MS; Yoon SC; Mazurowski MA J Magn Reson Imaging; 2019 Aug; 50(2):456-464. PubMed ID: 30648316 [TBL] [Abstract][Full Text] [Related]
71. Screening Performance of Digital Breast Tomosynthesis vs Digital Mammography in Community Practice by Patient Age, Screening Round, and Breast Density. Lowry KP; Coley RY; Miglioretti DL; Kerlikowske K; Henderson LM; Onega T; Sprague BL; Lee JM; Herschorn S; Tosteson ANA; Rauscher G; Lee CI JAMA Netw Open; 2020 Jul; 3(7):e2011792. PubMed ID: 32721031 [TBL] [Abstract][Full Text] [Related]
72. Glandular Tissue Component and Breast Cancer Risk in Mammographically Dense Breasts at Screening Breast US. Lee SH; Ryu HS; Jang MJ; Yi A; Ha SM; Kim SY; Chang JM; Cho N; Moon WK Radiology; 2021 Oct; 301(1):57-65. PubMed ID: 34282967 [TBL] [Abstract][Full Text] [Related]
73. Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type. Dilorenzo G; Telegrafo M; La Forgia D; Stabile Ianora AA; Moschetta M Eur J Radiol; 2019 Apr; 113():148-152. PubMed ID: 30927939 [TBL] [Abstract][Full Text] [Related]
74. Quantitative assessment of background parenchymal enhancement is associated with lifetime breast cancer risk in screening MRI. Yan R; Murakami W; Mortazavi S; Yu T; Chu FI; Lee-Felker S; Sung K Eur Radiol; 2024 Oct; 34(10):6358-6368. PubMed ID: 38683385 [TBL] [Abstract][Full Text] [Related]
75. Background parenchymal enhancement and breast cancer: a review of the emerging evidences about its potential use as imaging biomarker. Rella R; Contegiacomo A; Bufi E; Mercogliano S; Belli P; Manfredi R Br J Radiol; 2021 Mar; 94(1119):20200630. PubMed ID: 33035073 [TBL] [Abstract][Full Text] [Related]
76. Background ¹⁸F-FDG uptake in positron emission mammography (PEM): correlation with mammographic density and background parenchymal enhancement in breast MRI. Koo HR; Moon WK; Chun IK; Eo JS; Jeyanth JX; Chang JM; Cho N; Kang KW Eur J Radiol; 2013 Oct; 82(10):1738-42. PubMed ID: 23806533 [TBL] [Abstract][Full Text] [Related]
77. Hormonal Effects on Breast Density, Fibroglandular Tissue, and Background Parenchymal Enhancement. Heller SL; Young Lin LL; Melsaether AN; Moy L; Gao Y Radiographics; 2018; 38(4):983-996. PubMed ID: 29856684 [TBL] [Abstract][Full Text] [Related]
78. Analysis of background parenchymal enhancement (BPE) on contrast enhanced spectral mammography compared with magnetic resonance imaging. Luczynska E; Pawlak M; Piegza T; Popiela TJ; Heinze S; Dyczek S; Rudnicki W Ginekol Pol; 2021; 92(2):92-97. PubMed ID: 33448005 [TBL] [Abstract][Full Text] [Related]
79. MRI Background Parenchymal Enhancement Is Not Associated with Breast Cancer. Bennani-Baiti B; Dietzel M; Baltzer PA PLoS One; 2016; 11(7):e0158573. PubMed ID: 27379395 [TBL] [Abstract][Full Text] [Related]
80. Assessment of Background Parenchymal Enhancement at Dynamic Contrast-enhanced MRI in Predicting Breast Cancer Recurrence Risk. Arefan D; Zuley ML; Berg WA; Yang L; Sumkin JH; Wu S Radiology; 2024 Jan; 310(1):e230269. PubMed ID: 38259203 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]